Introduction {#S0001}
============

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the digestive system and account for less than 1% of all gastrointestinal tumors. These tumors are generally believed to be potentially malignant and less likely to have lymph node metastasis.[@CIT0001] For the patients with resectable high-risk GISTs, surgical resection followed by the administration of targeted therapy is the mainstay of therapy. Several risk stratification systems have been developed to estimate the risk of tumor recurrence. In multiple models, the main predictors of recurrence established were tumor mitotic rate, size, and location.[@CIT0002] The revised NIH consensus criteria by Joensuu et al in 2008 demonstrated that spontaneous or surgical rupture of the tumor worsened the prognosis of GIST. Incomplete resection also adversely affected the overall survival (OS).[@CIT0003]

Most GISTs (80%) are associated with gain-of-function mutations in the *KIT* gene, and approximately 10% are associated with mutations in the gene that encodes platelet-derived growth factor receptor-alpha (*PDGFRA*). Approximately 10% of GISTs are negative for both *KIT* and *PDGFRA* mutations.[@CIT0004] Mutations in both receptors drive downstream intracellular signaling pathways and lead to tumorigenesis.[@CIT0005]

Imatinib has become the first-line treatment for locally advanced/metastatic GIST and as adjuvant or neoadjuvant therapy. By competitively inhibiting the intracellular ATPbinding domain of tyrosine protein kinases, the *c-kit* gene plays a role in inhibiting intracellular signal transduction.[@CIT0006] All of the patients with high-risk GISTs were asked to take imatinib regularly after surgery, but we found that many patients did not comply with taking imatinib regularly during follow-up or did not take imatinib at all. To date, most were concerned with the duration of imatinib treatment and determination of whether to take imatinib.[@CIT0007]--[@CIT0009] However, no study has examined whether irregular imatinib treatment has an effect on progression-free survival (PFS) and OS.

To shed light on this issue, we have retrospectively investigated the clinical outcome of GIST patients who took imatinib irregularly and compared the outcomes of these patients with those of GIST patients who received regular imatinib therapy and those who were not treated with imatinib.

Patients and methods {#S0002}
====================

Between January 2009 and October 2018, we retrospectively gathered the clinical data from 120 consecutive patients diagnosed with GIST and treated at our institution. All patients had a histological diagnosis of GIST. The protocol of this study was approved by Tianjin Medical University General Hospital's Medical Ethics Committee and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient.

The inclusion criteria were as follows: (1) patients with primary GISTs who were not treated with preoperative chemotherapy or imatinib, (2) postoperative tumor risk categorization considered to be high-risk GIST according to the modified National Institutes of Health (NIH) consensus classification system, (3) patients with complete information after resection and follow-up results and (4) patients without distant metastasis. The exclusion criteria were (1) patients with any other malignancy and (2) any other serious concomitant diseases that might affect survival.

In the regular group, the patients were given imatinib for at least 3 years. Once the patients suffered a recurrence or metastasis, the dose of imatinib was increased by 200 mg/day or changed to sunitinib as second-line treatment. In the irregular group, the patients interrupted their imatinib treatment at irregular intervals; for example, the patients discontinued imatinib treatment or resumed treatment after 1 month. If the patients suffered tumor recurrence or metastasis, they received imatinib regularly. If the tumor developed further, the dose of imatinib was increased by 200 mg/day or changed to sunitinib as second-line treatment. In the observation group, during the follow-up period, if the patients were diagnosed with metastases or relapses, they received imatinib regularly. If the disease progressed, the dose was increased by 200 mg/day or changed to sunitinib. All patients received an initial dose of 400 mg/day. If a mutation of *KIT* exon 9 was present, the dose of imatinib was increased to 600 mg/day. In the event of intolerable complications, the dose was reduced to 300 mg/day.

In the regular treatment group, patients who interrupted their imatinib treatment mainly because of transient toxicities or reversible concomitant illnesses but restarted their treatment within 1 month without tumor reassessment were not considered to have irregular imatinib treatment; they were kept in the regular treatment group.

Follow-up {#S0002-S2001}
---------

Specially trained researchers used outpatient records, visits, letters, and telephone calls to follow-up the patients postoperatively, once every 3 months for the first 2 years, once every 6 months in the period between 3and 5 years after surgery, and once every year thereafter. All surviving patients were followed-up for more than 5 years. The survival time was defined as the time interval from surgery to the end of the follow-up period, the time of death, or the value entered in the follow-up database (such as death from other diseases).

Statistical analyses {#S0002-S2002}
--------------------

All statistical analyses were performed using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). Continuous variables were presented as median (IQR) and compared with a independent *t*--test. The categorical data were expressed as N (%) and analysed by the chi-squared test. The survival rates were calculated using the Kaplan--Meier method, which used the log-rank test to detect differences in the survival curves of the various sub-groups. The Cox proportional hazards model was used to analyse the prognostic factors of multiple factors. *P*-values \<0.05 were considered to indicate statistical significance.

Results {#S0003}
=======

Patients' characteristics {#S0003-S2001}
-------------------------

The clinical and histopathological tumor characteristics of the 120 patients are presented in [Table 1](#T0001){ref-type="table"}. There were no differences between the three treatment groups. Among the 120 patients with high-risk GIST, there were 71 males and 49 females; their median age was 63 years (range: 23--84). The locations of the tumors were in the stomach in 44 cases (36.7%), in the duodenum in 16 cases (13.3%), in the jejunoileum in 49 cases (40.8%), and in the omentum, colon, rectum, mesentery, or esophagus, in 11 cases (9.5%). Overall, the median tumor size was 9 cm with a range of 2.5--32.0 cm. There were 83 cases (69.2%) with mitotic counts ≤5 from 50 randomly selected high-power fields (HPF) and 37 cases (30.8%) with mitotic counts \>5 from 50 random HPF. There were 26 cases (21.7%) with intraoperative tumor rupture and 94 cases (78.3%) without intraoperative tumor rupture.Table 1Patient characteristics categorized by the treatment regimenCharacteristicsObservation groupIrregular treatment groupRegular treatment group*P-value*Age, years (median, range)63 (50--70)62 (53--71)64 (55--68)0.146Gender0.084 Male222227 Female102514Tumor site0.543 Stomach101816 Small intestine171814 Others51111Extent of radical surgery0.174 R0253838 R1 and R2793Tumor diameter, cm ≤54420.608 \>5 and ≤10172020 \>10112319Mitotic count (/50HPF)0.132 ≤514149 \>5183332Intraoperative tumor rupture0.137 Yes10115 No223636[^1]

Recurrence and survival outcome {#S0003-S2002}
-------------------------------

All patients completed the follow-up. The median follow-up interval was 64 months (range: 1--114). Fifty-eight patients (48.3%) developed postoperative recurrence and/or metastasis; In the observation group, 24 patients (75%) developed recurrence and metastasis, and in the irregular treatment group, 23 patients (48.9%) developed recurrence and metastasis. The recurrence rate in the irregular treatment group was higher than that in the observation group (*P*\<0.001). In the regular treatment group, 11 patients (26.8%) developed recurrence and metastasis, and the recurrence rate was lower than that in the observation and irregular treatment groups (*P*\<0.001).

Among the 120 patients, the median PFS was 45 months (range: 25--59). The 3-and 5-year PFS was 71.3% and 49.9%, respectively. In the regular treatment group, the median PFS was 50 months (range: 42--74). The 3-and 5-year PFS was 82.5% and 72.5%, respectively. In the irregular treatment group, the median PFS was 46 months (range: 25--61). The 3-and 5-year PFS was 63.1% and 51.7%, respectively. In the observation group, the median PFS was 27 months (range: 12--49). The 3-and 5-year PFS was 37.5% and 25.6%, respectively. There was a significant difference among the groups (*P*\<0.0001; [Figure 1](#F0001){ref-type="fig"}). The median OS of the 120 patients was 59 months (range: 47--78). The 3-and 5-year OS was 91.6% and 84.2%, respectively. In the regular therapy group, the median OS was 58 months (range: 45--81). The 3- and 5-year OS was 95.1 and 86.1%, respectively. In the irregular treatment group, the median OS was 63 months (range: 51--77). The 3- and 5-year OS was 91.3 and 87%, respectively. In the observation group, the median OS was 60 months (range: 46--79). The 3- and 5-year OS was 87.5% and 72%, respectively. There was no significant difference of OS between the groups (*P*=0.150; [Figure 2](#F0002){ref-type="fig"}).Figure 1Comparison of the progression-free survival (PFS) of patients in the regular therapy group, irregular treatment group and observation group (*P*\<0.0001).**Note:** ^a^Significant difference of PFS among the groups, log-rank test, *P*\<0.0001.Figure 2Comparison of the overall survival of patients in the regular therapy group, irregular treatment group and observation group (*P*=0.150).**Notes:** No significant difference of OS between the groups, log-rank test, *P*=0.150.

Prognostic factors {#S0003-S2003}
------------------

The Kaplan--Meier analysis showed that the extent of radical resection (*P*\<0.001) and intraoperative tumor rupture (*P*=0.005) were factors influencing OS ([Table 2](#T0002){ref-type="table"}). The multivariate Cox regression analysis showed that intraoperative tumor rupture (HR: 9.413; 95%CI: 1.318--67.199; *P*=0.025) and the extent of radical surgery (HR: 7.831; 95%CI: 1.687--36.171; *P*=0.009) were independent predictive factors of OS.Table 2Univariate analysis of patients' overall survivalCharacteristicsN (%)Median survival (months)*P-*valueGender0.388 Male71 (57.1)43 Female49 (49.3)48Age (years)0.344 \<6044 (36.7)67 ≥6076 (63.3)57Tumor site0.198 Stomach44 (36.7)58 Small intestine49 (40.8)65 Others27 (22.5)56Extent of radical surgery\<0.001 R0101 (84.2)65 R1 and R219 (15.8)34Tumor diameter, cm0.945 ≤510 (8.3)53 \>5 and ≤1057 (47.5)59 \>1053 (44.2)62Mitotic count (/50HPF) ≤583 (69.2)630.251 \>537 (30.8)58Intraoperative tumor rupture\<0.001 Yes26 (21.7)45 No94 (78.3)64[^2]

Discussion {#S0004}
==========

GIST is a mesenchymal tumor of the digestive system with a poor response to chemotherapy and radiotherapy. However, with R0 resection, it has been documented that 80% of the patients experience tumor recurrence within 5 years after surgery and will eventually die from the disease.[@CIT0010] This finding is likely attributable to the persistence of microscopic disease following surgery.

Imatinib is an oral, synthetic, small-molecule tyrosine kinase inhibitor that targets the *Kit* and *PDGFRA* proteins.[@CIT0011] Clinical trials of gastrointestinal stromal tumors demonstrating that adjuvant imatinib therapy improves the survival benefit of patients with advanced GIST before or after surgery and in the setting of unresectable or metastatic disease.[@CIT0012]--[@CIT0014] According to the Chinese consensus guidelines for the diagnosis and management of GIST, imatinib is the first-line therapy recommended for patients with intermediate or high risk gastrointestinal stromal tumor after surgical resection. The recommended adjuvant imatinib initial dosage is 400 mg/day.[@CIT0015] For intermediate-risk GIST, nongastric origin GIST, such as small intestinal or colorectal GIST, shows a higher risk of recurrence compared with gastric GIST. Therefore, 3-year adjuvant imatinib therapy is recommended, whereas 1-year adjuvant imatinib therapy is recommended for intermediate-risk gastric GIST.[@CIT0016] Patients with high-risk GIST are advised to receive at least 3 years of adjuvant therapy.[@CIT0009],[@CIT0017]

In clinical settings, a signiﬁcant proportion of patients choose to temporarily discontinue therapy, either with or without supervision by their physicians, because of recurrent toxicities, economic constraints, concomitant comorbidities, or desire to have a break from therapy. Thus, many studies have shed light on the effect of duration of imatinib treatment or the lack of imatinib treatment on the clinical outcome and showed that patients who received imatinib for a short duration or not at all have a lower rate of the 3- and 5-year PFS and OS.[@CIT0007],[@CIT0018],[@CIT0019] To date, no study has examined the effect of irregular imatinib treatment on the patients' outcome. Therefore, we analysed the effects of the irregular therapy on the overall survival and PFS. The results showed that patients receiving irregular imatinib treatment have a worse PFS rate and tended to be more likely to suffer tumor recurrence or metastasis compared with the regular treatment group (*P*\<0.0001). Nevertheless, no difference of the OS rates between the groups was observed (*P*=0.150), which may be due to their physicians treating these condition introducing or reintroducing imatinib regularly, increasing the doses of imatinib or changing to sunitinib as second-line treatment.

Adjuvant imatinib can be given according to the risk stratification. Thus, adequate risk stratification is necessary to select patients who will benefit the most from this therapy. The US National Institutes of Health (NIH) consensus system for risk classification assessment was based on tumor site, size and mitotic count.[@CIT0020] Many studies have shown that large tumor size and high mitotic count are associated with poor prognosis.[@CIT0014],[@CIT0021] Several current studies demonstrated that the long-term outcomes of patients with high-risk GIST improved due to prolongation of the imatinibtreatment for at least 5 years.[@CIT0022],[@CIT0023] However, an extended duration of adjuvant treatment will bring patients more economical burdens and drug sideeffect. Therefore, we need to assess what kinds of patients need prolongedduration of adjuvant imatinib treatment. In our study, extent of radical resection (*P*\<0.001) and intraoperative tumor rupture (*P*=0.005) were independently associated with OS. Multivariate analysis showed that complete resection was an important predictive factor in the prognosis of GISTs. Based on our results, if patients did not undergo an R0 resection or there was a rupture of tumor at the time of surgery, they should extend the duration of their adjuvant imatinib treatment for more than 3 years to achieve better clinical efficacy.

In conclusion, we demonstrated that irregular administration of imatinib was associated with a worse PFS; however, it did not influence the OS rate. Thus, whenever a tumor recurrence or metastasis is present. physicians should make every effort to treat the patients. The surgeons should minimize the likelihood of intraoperative tumor rupture and attempt to complete R0 resection. If a rupture of the tumor or an R0 resection could not be performed, adjuvant treatment for more than 36 months for high-risk GISTs should be administered, although the optimal treatment duration remains unclear. Complete resection, together with tumor-free resection margins and avoidance of tumor rupture and postoperative adjuvant imatinib treatment, remains the best option for a curative approach for resectable GISTs.
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[^1]: **Abbreviation:** HPF, High Power Field.
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